- $17.52m
- -$4.11m
- $11.20m
- 33
- 33
- 33
- 24
Annual balance sheet for Lipocine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 19.7 | 44.6 | 32.5 | 22 | 21.6 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0 | 0.247 | 0.08 | 0.052 | 0.12 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 25.3 | 46.4 | 34.1 | 22.9 | 22.3 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0 | 0.007 | 0.132 | 0.116 | 0.165 |
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 25.4 | 52.5 | 37.5 | 23 | 22.5 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 6.58 | 5.62 | 1.68 | 2.63 | 1.51 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 10 | 6.91 | 1.91 | 2.63 | 1.51 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 15.3 | 45.6 | 35.6 | 20.4 | 21 |
Total Liabilities & Shareholders' Equity | 25.4 | 52.5 | 37.5 | 23 | 22.5 |
Total Common Shares Outstanding |